SlideShare a Scribd company logo
Rheumatoid Arthritis in Family
Medicine
The new diagnostic guidelines and the role of Family Physicians
1
A I Haruna

April 23rd, 2020

Family Medicine
Purpose of this presentation
• To understand rationale for early recognition and treatment of RA

• To discuss the extent of involvement of the FP (open discussion)
Background
• RA as a chronic debilitating autoimmune disease

• Spontaneous remission without treatment is rare in RA 

• Inexorably leads to functional decline and premature mortality

• 10-12% of rheumatology patients in SW Nigeria (Adelowo et al, 2017), 

• 1% of general population globally, few studies in Africa (Dowman et al,
2012), regional variation, 30-60 yrs

• Rising because of urbanization and lifestyle
3
Goal of treatment
• Ultimate outcome (hope for the future)

• Early suppression of inflammation and
achievement of early remission

• prevent joint damage and disability

• Quite achievable with early treatment
• Joint damage and loss of function occur early in the disease process

• Radiographic evidence of erosions among 70% (within 3 years), and 25% (within 3 months)
Van der Heijde et al, 1995

• MSUS and MRI shown evidence of damage within weeks

• Delay in treatment commencement associated with poorer outcomes (Van der Linden et al,
2010 and Van Nies et al 2014)

• Two group comparison ‘<12 week and >12 week after symptom onset’ comparison

• 1.3 times higher rate of joint destruction and HR of 1.87 for not achieving DMARD-free
remission in the >12 week group

• All pointers to early referral to Rheumatologist

• Only 31% of referred patients get rheumatology assessment within the 12 week mark
5
How early is early?
• Window of opportunity: a limited period when the disease course can be altered or even reversed

• Cut off progressively decreased over the years: 5yrs, 2yrs, now 3mo v 12mo

• Very early RA: disease duration less than 3 months

• Late early RA: disease duration 3 months to 12 months

• Strongest predictor for dx remission at 6 months was a symptom duration of less than 12 weeks at the
time of treatment (Conaghen et al,1999)

• Clinical and radiographic outcomes were significantly better if treated before the 12 week mark (Nell et
al, 2004)

• ACR50 and DAS28 scores

• Response is nonlinear in terms of susceptibility to DMARDS (Emery et al, 2012)
6
We should diagnose early
• 1987 ACR criteria: developed with a population of patients with late disease, low
sensitivity recent RA

• Means patients with early RA may not fulfill these criteria
• Rationale for review of criteria: Poor sensitivity for early dx, shift of focus from
‘established to early dx’, outcome oriented medicine, biologics and new tests

• 2010 ACR: emphasis on identifying patients with

• short symptom duration, and poor prognosis, that will benefit from early initiation
of DMARD therapy

• to be applied to all patients with undifferentiated inflammatory synovitis
7
2010 ACR/EULAR CLASSIFICATION CRITERIA
FOR RA
Joint involvement
1 large joint 0
2-10 large joint 1
1-3 small joints (+- large joints) 2
4-10 small joints (+- large joints) 3
>10 joints (at least one small joint) 5
Serology
Negative RF and Negative ACPA 0
Low positive RF or low positive ACPA 2
High positive RF or high positive ACPA 3
Acute phase reactant
Normal CRP AND Normal ESR 0
Abnormal CRP or Abnormal ESR 1
Duration of symptoms
Sx <6 weeks 0
Sx > or = 6 weeks 1
A SCORE OF 6 OR MORE NEEDED FOR CLASSIFICATION AS DEFINITE RA

ANY SCORE BELOW 6 IS UA

MCP,MTP,DIP excluded
8
Exclude of inflammatory arthritis
• Undifferentiated arthritis: 30% remit, 30% develop RA, 20% remain UA

• 3 or more swollen joints, MTP/MCP involvement, EMS >30 minutes
• Extra-articular manifestations: late in RA, early in SLE, ReA, PsA,
Sarcoidosis help rule out differentials

• CBC, ESR, RF, CRP, ACPA to confirm RA, 

• X-rays, MRI, MSUS
Prognostic Factors
Predictors of disease persistence / erosive
arthritis
Predictors of disease severity
Female gender
High joint count
Positive RF, ACPA
Raised acute phase reactants (ESR, CRP)
Duration of symptoms High HAQ score
Hand involvement Shared epitope
Erosions on X-ray Erosive disease
HAQ: Health Assessment Questionnaire

ACPA: Anticyclic Citrillunated Peptide Antibody
• FM based predictors: Family and social support, environmental factors

• High HAQ score: either at diagnosis or at 1 year (Wiles et al, 2000)

• ESR and CRP: Utility more than additive

• RF quantitative

• Shared epitope (SE) and family history

• Early morning stiffness no more relevant (Funovits et al, 2010)

• Smoking is the strongest environmental risk factor, formation of ACPA (esp with SE)
Phases up to the development of RA
Genetic factors
Environmental factors
Systemic autoimmunity
symptoms without clinical arthritis
Unclassified arthritis
RA
12
Symptoms
Time
Response to DMARDS
12 wk
12 wk
Nonlinear response to DMARDS
In Summary
• 2010 ACR/EULAR classification criteria will push the numbers up

• more objectivity, shifts attention to early disease, congest rheumatology
clinic

• Early identification and institution of treatment is the standard (presented
later)

• Prognostic factors equally as necessary
13
Discussion
• What roles do FP play? Identify and diagnose early RA

• At what point do we refer? As soon as we ID inflammatory arthritis

• Other thoughts…..
14
Thank you
15

More Related Content

What's hot

Point of Care
Point of CarePoint of Care
Point of Care
growell
 
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
Ching-wen Lu
 
Sickle cell and depression final
Sickle cell and depression finalSickle cell and depression final
Sickle cell and depression final
Kimberly Reger
 
High ED Utilization and Perceptions of Opioid Addiction
High ED Utilization and Perceptions of Opioid AddictionHigh ED Utilization and Perceptions of Opioid Addiction
High ED Utilization and Perceptions of Opioid Addiction
Hants Williams, Ph.D., RN
 
Concepts of Screening for disease
Concepts of Screening for diseaseConcepts of Screening for disease
Concepts of Screening for disease
Mohan Jangwal
 

What's hot (20)

Women's Brain Project- Alzheimer's disease under the sex and gender lens: the...
Women's Brain Project- Alzheimer's disease under the sex and gender lens: the...Women's Brain Project- Alzheimer's disease under the sex and gender lens: the...
Women's Brain Project- Alzheimer's disease under the sex and gender lens: the...
 
Falls and cardiovascular disease
Falls and cardiovascular diseaseFalls and cardiovascular disease
Falls and cardiovascular disease
 
Protective Factors in Suicide (Journal Club)
Protective Factors in Suicide (Journal Club)Protective Factors in Suicide (Journal Club)
Protective Factors in Suicide (Journal Club)
 
Finding the Path to Improved Recognition and Management of Tardive Dyskinesia
Finding the Path to Improved Recognition and Management of Tardive DyskinesiaFinding the Path to Improved Recognition and Management of Tardive Dyskinesia
Finding the Path to Improved Recognition and Management of Tardive Dyskinesia
 
Influence of Interns, Residents and Attendings on Inpaitient Length of Stay 4...
Influence of Interns, Residents and Attendings on Inpaitient Length of Stay 4...Influence of Interns, Residents and Attendings on Inpaitient Length of Stay 4...
Influence of Interns, Residents and Attendings on Inpaitient Length of Stay 4...
 
Geriatric Oncology
Geriatric OncologyGeriatric Oncology
Geriatric Oncology
 
Point of Care
Point of CarePoint of Care
Point of Care
 
Interns Account for Much of the Variation in Length of Stay on a General Medi...
Interns Account for Much of the Variation in Length of Stay on a General Medi...Interns Account for Much of the Variation in Length of Stay on a General Medi...
Interns Account for Much of the Variation in Length of Stay on a General Medi...
 
9
99
9
 
The Changing Face of Trauma Care
The Changing Face of Trauma Care The Changing Face of Trauma Care
The Changing Face of Trauma Care
 
Screening lecture for sims Lahore and Post Graduatestudents 2017
Screening lecture for sims Lahore  and Post Graduatestudents 2017Screening lecture for sims Lahore  and Post Graduatestudents 2017
Screening lecture for sims Lahore and Post Graduatestudents 2017
 
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
Individuals living with lupus: findings from the LUPUS UK Members Survey 2014
 
Noon conference specialty talk ccu 5-7-19
Noon conference specialty talk   ccu 5-7-19Noon conference specialty talk   ccu 5-7-19
Noon conference specialty talk ccu 5-7-19
 
Sickle cell and depression final
Sickle cell and depression finalSickle cell and depression final
Sickle cell and depression final
 
Where’s the evidence that screening for distress benefits cancer patients?
Where’s the evidence that screening for distress benefits cancer patients?Where’s the evidence that screening for distress benefits cancer patients?
Where’s the evidence that screening for distress benefits cancer patients?
 
Carle Palliative Care Journal Club 1/15/2020
Carle Palliative Care Journal Club 1/15/2020Carle Palliative Care Journal Club 1/15/2020
Carle Palliative Care Journal Club 1/15/2020
 
High ED Utilization and Perceptions of Opioid Addiction
High ED Utilization and Perceptions of Opioid AddictionHigh ED Utilization and Perceptions of Opioid Addiction
High ED Utilization and Perceptions of Opioid Addiction
 
Epidemiological Characteristics Of Neglected Cases Of Intraocular Retinoblast...
Epidemiological Characteristics Of Neglected Cases Of Intraocular Retinoblast...Epidemiological Characteristics Of Neglected Cases Of Intraocular Retinoblast...
Epidemiological Characteristics Of Neglected Cases Of Intraocular Retinoblast...
 
Concepts of Screening for disease
Concepts of Screening for diseaseConcepts of Screening for disease
Concepts of Screening for disease
 
Frequency of migraine headaches in patients with fibromyalgia
Frequency of migraine headaches in patients with fibromyalgiaFrequency of migraine headaches in patients with fibromyalgia
Frequency of migraine headaches in patients with fibromyalgia
 

Similar to Rheumatoid Arthritis in Family Medicine

Pm 4.50 hochberg
Pm 4.50 hochbergPm 4.50 hochberg
Pm 4.50 hochberg
plmiami
 
Out Come Of R
Out Come Of  ROut Come Of  R
Out Come Of R
drmomusa
 
Central serous chorioretinopathy DR AJAY DUDANI
Central serous chorioretinopathy DR AJAY DUDANICentral serous chorioretinopathy DR AJAY DUDANI
Central serous chorioretinopathy DR AJAY DUDANI
AjayDudani1
 
3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis
Amer
 

Similar to Rheumatoid Arthritis in Family Medicine (20)

Role of Tofacitinib in Rheumatoid Arthritis
Role of Tofacitinib in Rheumatoid ArthritisRole of Tofacitinib in Rheumatoid Arthritis
Role of Tofacitinib in Rheumatoid Arthritis
 
Rheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and TreatmentRheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and Treatment
 
Pm 4.50 hochberg
Pm 4.50 hochbergPm 4.50 hochberg
Pm 4.50 hochberg
 
Out Come Of R
Out Come Of  ROut Come Of  R
Out Come Of R
 
Pall RT.pptx
Pall RT.pptxPall RT.pptx
Pall RT.pptx
 
Monitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientMonitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patient
 
rheumatoid arthritis
rheumatoid arthritisrheumatoid arthritis
rheumatoid arthritis
 
Treat to target in inflammatory diseases SMMI 2018
Treat to target in inflammatory diseases SMMI 2018Treat to target in inflammatory diseases SMMI 2018
Treat to target in inflammatory diseases SMMI 2018
 
NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosis
 
High Risk Smoldering Myeloma
High Risk Smoldering MyelomaHigh Risk Smoldering Myeloma
High Risk Smoldering Myeloma
 
Early and late onset multiple sclerosis
Early and late onset multiple sclerosisEarly and late onset multiple sclerosis
Early and late onset multiple sclerosis
 
Deciding When Hospice is Needed
Deciding When Hospice is NeededDeciding When Hospice is Needed
Deciding When Hospice is Needed
 
Deciding When Hospice Care is Needed | VITAS Healthcare
Deciding When Hospice Care is Needed | VITAS HealthcareDeciding When Hospice Care is Needed | VITAS Healthcare
Deciding When Hospice Care is Needed | VITAS Healthcare
 
Lupus Nephritis Dilemma - Prof. Mohsen El Kosi
Lupus Nephritis Dilemma - Prof. Mohsen El KosiLupus Nephritis Dilemma - Prof. Mohsen El Kosi
Lupus Nephritis Dilemma - Prof. Mohsen El Kosi
 
presentation.pptx
presentation.pptxpresentation.pptx
presentation.pptx
 
Essential Rheumatology for PMR residents.pptx
Essential Rheumatology for PMR residents.pptxEssential Rheumatology for PMR residents.pptx
Essential Rheumatology for PMR residents.pptx
 
PROSTATE CANCER IN NUTSHELL
PROSTATE CANCER IN NUTSHELLPROSTATE CANCER IN NUTSHELL
PROSTATE CANCER IN NUTSHELL
 
Central serous chorioretinopathy DR AJAY DUDANI
Central serous chorioretinopathy DR AJAY DUDANICentral serous chorioretinopathy DR AJAY DUDANI
Central serous chorioretinopathy DR AJAY DUDANI
 
3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis3 evaluation and management of rheumatoid arthritis
3 evaluation and management of rheumatoid arthritis
 
Prostate cancer Risk stratification and choice of initial treatment final.pptx
Prostate cancer Risk stratification and choice of initial treatment final.pptxProstate cancer Risk stratification and choice of initial treatment final.pptx
Prostate cancer Risk stratification and choice of initial treatment final.pptx
 

Recently uploaded

Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
pchutichetpong
 

Recently uploaded (20)

Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptx
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
 
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptxStorage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
 
What is 5 steps for dental health care ?
What is 5 steps for dental health care ?What is 5 steps for dental health care ?
What is 5 steps for dental health care ?
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
Ayurveda hair cosmetlogy on Indralupta or Alopecia.pptx
Ayurveda hair cosmetlogy on Indralupta or Alopecia.pptxAyurveda hair cosmetlogy on Indralupta or Alopecia.pptx
Ayurveda hair cosmetlogy on Indralupta or Alopecia.pptx
 
QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020
 
What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
 
Dehradun ❤CALL Girls 8901183002 ❤ℂall Girls IN Dehradun ESCORT SERVICE❤
Dehradun ❤CALL Girls  8901183002 ❤ℂall  Girls IN Dehradun ESCORT SERVICE❤Dehradun ❤CALL Girls  8901183002 ❤ℂall  Girls IN Dehradun ESCORT SERVICE❤
Dehradun ❤CALL Girls 8901183002 ❤ℂall Girls IN Dehradun ESCORT SERVICE❤
 
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
 
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
 

Rheumatoid Arthritis in Family Medicine

  • 1. Rheumatoid Arthritis in Family Medicine The new diagnostic guidelines and the role of Family Physicians 1 A I Haruna April 23rd, 2020 Family Medicine
  • 2. Purpose of this presentation • To understand rationale for early recognition and treatment of RA • To discuss the extent of involvement of the FP (open discussion)
  • 3. Background • RA as a chronic debilitating autoimmune disease • Spontaneous remission without treatment is rare in RA • Inexorably leads to functional decline and premature mortality • 10-12% of rheumatology patients in SW Nigeria (Adelowo et al, 2017), • 1% of general population globally, few studies in Africa (Dowman et al, 2012), regional variation, 30-60 yrs • Rising because of urbanization and lifestyle 3
  • 4. Goal of treatment • Ultimate outcome (hope for the future) • Early suppression of inflammation and achievement of early remission • prevent joint damage and disability • Quite achievable with early treatment
  • 5. • Joint damage and loss of function occur early in the disease process • Radiographic evidence of erosions among 70% (within 3 years), and 25% (within 3 months) Van der Heijde et al, 1995 • MSUS and MRI shown evidence of damage within weeks • Delay in treatment commencement associated with poorer outcomes (Van der Linden et al, 2010 and Van Nies et al 2014) • Two group comparison ‘<12 week and >12 week after symptom onset’ comparison • 1.3 times higher rate of joint destruction and HR of 1.87 for not achieving DMARD-free remission in the >12 week group • All pointers to early referral to Rheumatologist • Only 31% of referred patients get rheumatology assessment within the 12 week mark 5
  • 6. How early is early? • Window of opportunity: a limited period when the disease course can be altered or even reversed • Cut off progressively decreased over the years: 5yrs, 2yrs, now 3mo v 12mo • Very early RA: disease duration less than 3 months • Late early RA: disease duration 3 months to 12 months • Strongest predictor for dx remission at 6 months was a symptom duration of less than 12 weeks at the time of treatment (Conaghen et al,1999) • Clinical and radiographic outcomes were significantly better if treated before the 12 week mark (Nell et al, 2004) • ACR50 and DAS28 scores • Response is nonlinear in terms of susceptibility to DMARDS (Emery et al, 2012) 6
  • 7. We should diagnose early • 1987 ACR criteria: developed with a population of patients with late disease, low sensitivity recent RA • Means patients with early RA may not fulfill these criteria • Rationale for review of criteria: Poor sensitivity for early dx, shift of focus from ‘established to early dx’, outcome oriented medicine, biologics and new tests • 2010 ACR: emphasis on identifying patients with • short symptom duration, and poor prognosis, that will benefit from early initiation of DMARD therapy • to be applied to all patients with undifferentiated inflammatory synovitis 7
  • 8. 2010 ACR/EULAR CLASSIFICATION CRITERIA FOR RA Joint involvement 1 large joint 0 2-10 large joint 1 1-3 small joints (+- large joints) 2 4-10 small joints (+- large joints) 3 >10 joints (at least one small joint) 5 Serology Negative RF and Negative ACPA 0 Low positive RF or low positive ACPA 2 High positive RF or high positive ACPA 3 Acute phase reactant Normal CRP AND Normal ESR 0 Abnormal CRP or Abnormal ESR 1 Duration of symptoms Sx <6 weeks 0 Sx > or = 6 weeks 1 A SCORE OF 6 OR MORE NEEDED FOR CLASSIFICATION AS DEFINITE RA ANY SCORE BELOW 6 IS UA MCP,MTP,DIP excluded 8
  • 9. Exclude of inflammatory arthritis • Undifferentiated arthritis: 30% remit, 30% develop RA, 20% remain UA • 3 or more swollen joints, MTP/MCP involvement, EMS >30 minutes • Extra-articular manifestations: late in RA, early in SLE, ReA, PsA, Sarcoidosis help rule out differentials • CBC, ESR, RF, CRP, ACPA to confirm RA, • X-rays, MRI, MSUS
  • 10. Prognostic Factors Predictors of disease persistence / erosive arthritis Predictors of disease severity Female gender High joint count Positive RF, ACPA Raised acute phase reactants (ESR, CRP) Duration of symptoms High HAQ score Hand involvement Shared epitope Erosions on X-ray Erosive disease HAQ: Health Assessment Questionnaire ACPA: Anticyclic Citrillunated Peptide Antibody
  • 11. • FM based predictors: Family and social support, environmental factors • High HAQ score: either at diagnosis or at 1 year (Wiles et al, 2000) • ESR and CRP: Utility more than additive • RF quantitative • Shared epitope (SE) and family history • Early morning stiffness no more relevant (Funovits et al, 2010) • Smoking is the strongest environmental risk factor, formation of ACPA (esp with SE)
  • 12. Phases up to the development of RA Genetic factors Environmental factors Systemic autoimmunity symptoms without clinical arthritis Unclassified arthritis RA 12 Symptoms Time Response to DMARDS 12 wk 12 wk Nonlinear response to DMARDS
  • 13. In Summary • 2010 ACR/EULAR classification criteria will push the numbers up • more objectivity, shifts attention to early disease, congest rheumatology clinic • Early identification and institution of treatment is the standard (presented later) • Prognostic factors equally as necessary 13
  • 14. Discussion • What roles do FP play? Identify and diagnose early RA • At what point do we refer? As soon as we ID inflammatory arthritis • Other thoughts….. 14